{"id":41537,"date":"2021-12-30T11:20:45","date_gmt":"2021-12-30T11:20:45","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=41537"},"modified":"2022-01-04T11:43:50","modified_gmt":"2022-01-04T11:43:50","slug":"assessment-of-the-nutritional-profile-of-women-with-breast-cancer-from-the-agadir-region-south-of-morocco","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol14no4\/assessment-of-the-nutritional-profile-of-women-with-breast-cancer-from-the-agadir-region-south-of-morocco\/","title":{"rendered":"Assessment of the Nutritional Profile of Women with Breast Cancer from the Agadir Region (South of Morocco)"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

Among tumors, breast cancer (BC) is one of the most diagnosed with an incidence and mortality rate reaching respectively 24.5% and 15.5% worldwide1<\/sup>. BC is a complex condition subdivided into molecular subtypes related to the status of estrogen (ER) and progesterone (PR) receptors, and human epidermal growth factor (HER2) receptors. Similarly, two\u00a0phenotypic subtypes of expression of hormonal receptors in the epithelial cells of the ducts or lobules of the mammary glands are distinguished; luminal A cells have more ER than luminal B cells. BC may have a different etiology depending on the status of the receptors2<\/sup>. For\u00a0example, the literature reported a strong binding of ER + type to reproductive factors3<\/sup>, hormone replacement therapy in menopause4<\/sup> and the mass body index (BMI)5<\/sup>. Diet also plays an important role in the development of BC6<\/sup>. BC was favored by cereals and available sugars\u00a0and inversely related to vegetables and polyunsaturated fatty acids7-8<\/sup> .Nutrition is also of major importance as many patients (40%) make lifestyle changes, including diet, following a positive diagnosis of cancer9-10<\/sup>. Some studies have reported that patients with BC have an\u00a0inadequate diet11-12<\/sup>, which may contribute to their deteriorating health status during treatment13<\/sup>. A balanced and healthy diet could prevent the occurrence of BC, improve the state of health of patients and prevent co-morbidities linked to this condition, particularly\u00a0cardiovascular diseases which represent the most frequent comorbidity and the main cause of death unrelated to BC in women over 50 years of age14<\/sup>.<\/p>\n

Incidence (36.9%) and mortality (24.7%) values linked to BC in Morocco are higher than the world average15<\/sup>. This raises questions about the etiology of this disease, especially with regard to the diet and quality of life of Moroccan women. To our knowledge, no study has\u00a0been undertaken to evaluate the nutritional status of women with BC in Morocco. This study aims at assessing the nutritional profile of women from the Agadir region (southern Morocco) with BC, in relation to their pathological status and their anthropometric characteristics.<\/p>\n

Materials and Methods<\/strong><\/p>\n

Sampling and Data Collection<\/strong><\/p>\n

The study was carried out between January 2019 and February 2020. A convenience sample of 91 women with BC was recruited from the Hassan II Regional Hospital Center and the Agadir Regional Center of Oncology. All subjects were initially informed that their biological and anthropometric data would be exploited for scientific purposes. All participants signed\u00a0informed and express consent. The study was authorized by the Moroccan Ministry of Health (authorization number 3851\/02092017) and approved by the Moroccan Association of Research and Ethics (approval number 4\/REC\/20). Recruitment concerned patients with BC\u00a0without metastases, with postoperative, preoperative, ongoing or completed treatment, and without any sign of recurrence or relapse. The exclusion criteria were metastatic BC and other cancers, decompensated heart disease, hepatic failure, renal failure, psychiatric illness and any\u00a0refusal to sign consent. Data were collected using a questionnaire in direct interviews, face-to-face, and from medical records. They included education level, occupation, marital status, parity and hormonal status of the respondent (menopausal status and use of contraception). BCs have been classified into molecular subtypes based on the expression of hormone\u00a0receptors (ER + \/ ER-; PR + \/ PR-, HER2 +\/\u2013; luminal A and luminal B). Body mass, height, waist circumference and hip circumference were determined and compared to WHO recommendations16<\/sup>. Abdominal obesity was indicated if the waist circumference was \u2265 88 cm or 0.85 for the waist-to-hip ratio (TT \/ TH).<\/p>\n

The body analysis was performed using a Tanita\u00ae BC 418 MA analyzer (Tanita Corporation, USA) which determines weight, BMI, percentage fat mass (FM), lean mass (LM) and visceral fat (VF). All of these measurements were carried out while standing. The BMI was classified according to the WHO recommendations as underweight (BMI <18.5 kg \/ m2), normal weight\u00a0(18.5 \u2264 BMI 24.9 kg \/ m2), overweight (25 \u2264 BMI 29.9 kg \/ m2) and obese (BMI> 30 kg \/ m2). Based on their body fat (BF) percentage, the patients were classified into a lean group, a normal BF group and an excess BF group (with body fat levels <24%, between 24% and 33%, and > 33% respectively). All patients were asked to complete three non-consecutive days\u2019\u00a0\u00a0food diary (two working days and one weekend day). To estimate food servings, photos of household measurements such as plates, spoons, glasses, bowls, and cups were shown to patients using SuviMax survey books. Nutritional intake calculations were performed using Nutrilog\u00ae<\/sup> software (Ver2.20). Several nutritional variables were evaluated, including energy\u00a0intake, macronutrients (proteins, carbohydrates, lipids, cholesterol and fiber), vitamins (A, D, E, B2, B6, folic acid, B12, C), minerals and oligoelements (calcium, iron, magnesium, zinc, selenium). Due to the lack of standards or recommended intakes specific to the Moroccan population, nutritional intakes were determined by referring to those recommended by The Institute of Medicine of the National Academies (USA)17<\/sup>.<\/p>\n

Statistical analyzes<\/strong><\/p>\n

Statistical analyzes were performed using SPSS-20 software. Data represented mean \u00b1 for quantitative variables and as a percentage for qualitative variables. Comparisons between groups were made using analysis of variance (ANOVA) and Student’s\u00a0“t” test. Pearson’s correlation test was used to assess associations between nutrient intakes and anthropometric parameters of different groups.<\/p>\n

Results<\/strong><\/p>\n

Table 1 summarizes the socio-demographic and pathological characteristics of the patients. The results show that 79% were from the urban areas, close to 65% were illiterate and only 3.3% had university level. Three quarters were housewives. The majority were married\u00a0(56%). The menopausal status represented 54% and 65% of the respondents used oral contraception.<\/p>\n

Table 1: General data of the respondents.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Residence <\/strong><\/td>\n<\/td>\nMenopausal status<\/strong><\/td>\n\u00a0<\/strong><\/td>\n<\/tr>\n
Rural<\/td>\n20.88 % (n = 19)<\/td>\nPre-menopausal<\/td>\n46.15 % (n = 42)<\/td>\n<\/tr>\n
Urban<\/td>\n79.12 % (n = 72)<\/td>\nPost-menopausal<\/td>\n53.85 % (n = 49)<\/td>\n<\/tr>\n
Marital status<\/strong><\/td>\n\u00a0<\/strong><\/td>\nEducation level<\/strong><\/td>\n<\/td>\n<\/tr>\n
Singles<\/td>\n13.19 % (n = 12)<\/td>\nIlliterate<\/td>\n64.83 % (n = 59)<\/td>\n<\/tr>\n
Brides<\/td>\n56.04 % (n = 51)<\/td>\nPrimary<\/td>\n18.68 % (n = 17)<\/td>\n<\/tr>\n
Divorced<\/td>\n16.48 % (n = 15)<\/td>\nSecondary<\/td>\n13.19 % (n = 12)<\/td>\n<\/tr>\n
Widows<\/td>\n14.29 % (n = 13)<\/td>\nUniversity<\/td>\n3.30 % (n = 3)<\/td>\n<\/tr>\n
Oral contraception<\/strong><\/td>\n\u00a0<\/strong><\/td>\nWorking status<\/strong><\/td>\n\u00a0<\/strong><\/td>\n<\/tr>\n
Yes<\/td>\n64.84 % (n = 59)<\/td>\nManager<\/td>\n2.21 % (n = 2)<\/td>\n<\/tr>\n
No<\/td>\n35.16 % (n = 32)<\/td>\nEmployee<\/td>\n4.40 % (n = 4)<\/td>\n<\/tr>\n
\u00a0<\/strong><\/td>\n\u00a0<\/strong><\/td>\nWorker<\/td>\n12.08 % (n= 11)<\/td>\n<\/tr>\n
<\/td>\n<\/td>\nHousewife<\/td>\n81.31 % (n= 74)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 2 shows the anthropometric parameters of the interviewees. The average age was 48.54 \u00b1 9.83 years. Their weight and BMI were 68.69 \u00b1 11.60 and 28.56 \u00b1 4.73 respectively. Postmenopausal women had a significantly higher mean weight and BMI than non-menopausal women (p < 0.015). We found that about 75% of them were overweight or obese and 84% had a very high waist circumference. The patients also presented an excess of BF. The BF rate was significantly higher in postmenopausal than in premenopausal women (p < 0.007).<\/p>\n

Table 2: Anthropometric parameters of the respondents<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
<\/td>\nAge<\/strong><\/td>\nWeight \u00a0( kg)<\/strong><\/td>\nHeight\u00a0 (cm)<\/strong><\/td>\nBMI (kg\/m2)<\/strong><\/td>\nWC (cm)<\/strong><\/td>\nHC (cm)<\/strong><\/td>\nWT\/HC<\/strong><\/td>\nFM (%)<\/strong><\/td>\nLM (%)<\/strong><\/td>\nVF (kg)<\/strong><\/td>\n<\/tr>\n
Average<\/strong><\/td>\n48.54<\/td>\n68.69<\/td>\n155.68<\/td>\n28.56<\/td>\n96.81<\/td>\n104.38<\/td>\n0.93<\/td>\n36.54<\/td>\n42.91<\/td>\n7.84<\/td>\n<\/tr>\n
Standard deviation<\/strong><\/td>\n9.83<\/td>\n11.60<\/td>\n6.50<\/td>\n4.73<\/td>\n10.22<\/td>\n10.90<\/td>\n0.07<\/td>\n6.98<\/td>\n4.41<\/td>\n2.93<\/td>\n<\/tr>\n
Minimum value<\/strong><\/td>\n26<\/td>\n44<\/td>\n138<\/td>\n19.10<\/td>\n64<\/td>\n70<\/td>\n0.78<\/td>\n17.10<\/td>\n30.30<\/td>\n1<\/td>\n<\/tr>\n
Maximum value<\/strong><\/td>\n74<\/td>\n97.20<\/td>\n169<\/td>\n39.90<\/td>\n119<\/td>\n129<\/td>\n1.15<\/td>\n48.40<\/td>\n53.70<\/td>\n14<\/td>\n<\/tr>\n
Percentiles<\/strong><\/td>\n25<\/td>\n42<\/td>\n60.70<\/td>\n151<\/td>\n24.90<\/td>\n90<\/td>\n98<\/td>\n0.88<\/td>\n30.80<\/td>\n39.50<\/td>\n6<\/td>\n<\/tr>\n
50<\/td>\n49<\/td>\n68.20<\/td>\n156<\/td>\n28.10<\/td>\n99<\/td>\n104<\/td>\n0.93<\/td>\n37.30<\/td>\n42.80<\/td>\n8<\/td>\n<\/tr>\n
75<\/td>\n54<\/td>\n77.60<\/td>\n159<\/td>\n32.20<\/td>\n103<\/td>\n113<\/td>\n0.97<\/td>\n42.60<\/td>\n46.10<\/td>\n10<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

BMI: body mass index, WC: waist circumference, HC: hip circumference, FM: fat mass, LM: lean mass, VF: visceral fat.<\/p>\n

Table 3 displays the intakes of various nutrients among the participants in our survey. The majority of them (79%) had energy intake well above the recommendations. The contribution of lipids in these intakes was excessive for 46% of patients. As for the qualitative aspect, the\u00a0intakes of saturated fatty acids were only high in 14% of cases. Intake of saturated fatty acids was positively correlated with tumor size (r = 0.233 and p = 0.026).<\/p>\n

Table 3: Total daily intake of nutrients<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Macronutrients and energy<\/strong><\/td>\nMean (SD)<\/strong><\/td>\nRecommendations (INMA, 2005)<\/strong><\/td>\nPatients with non-standard intake (%)<\/strong><\/td>\n<\/tr>\n
Energy (Kcal\/day)<\/td>\n2562 (606)<\/td>\n1800 \u2013 2000<\/td>\n<\/td>\n<\/tr>\n
Proteins (%)<\/td>\n12.99 (3.88)<\/td>\n12 \u2013 15<\/td>\n+35.21<\/td>\n<\/tr>\n
Proteins (g\/Kg\/day)<\/td>\n1.22 (0.43)<\/td>\n0.8 \u2013 1<\/td>\n+26.26<\/td>\n<\/tr>\n
Carbohydrates (%)<\/td>\n52.57 (10.83)<\/td>\n55 \u2013 60<\/td>\n+42<\/td>\n<\/tr>\n
Sugar (%)<\/td>\n12.15 (5.41)<\/td>\n< 5<\/td>\n+58<\/td>\n<\/tr>\n
Lipids (%)<\/td>\n34.54 (10.42)<\/td>\n25 \u2013 35<\/td>\n+46<\/td>\n<\/tr>\n
Fibres (g)<\/td>\n32.14 (16.63)<\/td>\n25 \u2013 30<\/td>\n-31<\/td>\n<\/tr>\n
Cholesterol (mg)<\/td>\n300 (262.9)<\/td>\n180 \u2013 205<\/td>\n+40<\/td>\n<\/tr>\n
SFA (%)<\/td>\n7.1 (2.63)<\/td>\n< 10<\/td>\n+14<\/td>\n<\/tr>\n
MUFA (%)<\/td>\n20.84 (7.75)<\/td>\n15 \u2013 20<\/td>\n+50.55<\/td>\n<\/tr>\n
PUFA (%)<\/td>\n4.41 (2.34)<\/td>\n5 – 10<\/td>\n+53<\/td>\n<\/tr>\n
Minerals (mg)<\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Calcium<\/td>\n551 (252)<\/td>\n88 – 110<\/td>\n-92<\/td>\n<\/tr>\n
Phosphorus<\/td>\n1302 (477)<\/td>\n25 – 45<\/td>\n+93<\/td>\n<\/tr>\n
Iron<\/td>\n13.75 (9.49)<\/td>\n8.1 – 18<\/td>\n+24<\/td>\n<\/tr>\n
Magnesium<\/td>\n303.9 (120.54)<\/td>\n265 – 320<\/td>\n-43<\/td>\n<\/tr>\n
Zinc<\/td>\n8.17 (3.43)<\/td>\n6.8 – 8<\/td>\n-35<\/td>\n<\/tr>\n
Selenium<\/td>\n48.79 (22.6)<\/td>\n45 – 55<\/td>\n-48<\/td>\n<\/tr>\n
Vitamins<\/strong><\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
A (mcg)<\/td>\n275.47 (236.4)<\/td>\n500 \u2013 700<\/td>\n-66<\/td>\n<\/tr>\n
\u200eD (mcg)<\/td>\n9.62 (5.22)<\/td>\n15 \u2013 20<\/td>\n-45<\/td>\n<\/tr>\n
\u200eE (mg)<\/td>\n14.05 (7.94)<\/td>\n12 \u2013 15<\/td>\n-91<\/td>\n<\/tr>\n
\u200eC (mg)<\/td>\n115.14 (96.46)<\/td>\n60 \u2013 65<\/td>\n-32<\/td>\n<\/tr>\n
B1 (mg)<\/td>\n1.16 (0.46)<\/td>\n0.9 \u2013 1.1<\/td>\n-24<\/td>\n<\/tr>\n
B2 (mg)<\/td>\n1.27 (1.13)<\/td>\n0.9 \u2013 1.1<\/td>\n-35<\/td>\n<\/tr>\n
B6 (mg)<\/td>\n1.96 (0.84)<\/td>\n1.1 \u2013 1.3<\/td>\n-10<\/td>\n<\/tr>\n
B9 (mg)<\/td>\n311 (133.73)<\/td>\n320 \u2013 400<\/td>\n-62<\/td>\n<\/tr>\n
B12 (mg)<\/td>\n3.1 (2.41)<\/td>\n2 \u2013 2.4<\/td>\n-54<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids, +: above standard, -: substandard<\/p>\n

The consumption of monounsaturated fatty acids was high in 50.55%, and low in 23% of patients (Table 3). Intakes of polyunsaturated fatty acids were very high in nearly 53% of patients and only 6.6% had very low intakes. The consumption of sugars was important.\u00a0About 42% had a very high intake, with a high consumption of fast sugars in 58%. As for proteins, the intake was satisfactory in 61.54% and low in only 13.2% of cases. No significant difference was observed between the cancer subtypes except for the sugars intake that was significantly very high in women with RP + compared to RP- subtype (table 4).<\/p>\n

Table 4: Energy and macronutrient intake according to breast cancer subtypes<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\nEstrogen receptor<\/strong><\/td>\nProgesterone receptor<\/strong><\/td>\nHER<\/strong><\/td>\nPhenotype<\/strong><\/td>\n<\/tr>\n
<\/td>\nER+<\/p>\n

(n = 71)<\/td>\n

ER-<\/p>\n

(n = 20)<\/td>\n

PR+<\/p>\n

(n = 65)<\/td>\n

PR-<\/p>\n

(n = 26)<\/td>\n

HER+<\/p>\n

(n = 27)<\/td>\n

HER-<\/p>\n

(n = 64)<\/td>\n

Luminal A (n = 45)<\/td>\nLuminal B (n = 28)<\/td>\n<\/tr>\n
Energy (Kcal\/day)<\/strong><\/td>\n2565<\/p>\n

\u00b1 60<\/td>\n

2554<\/p>\n

\u00b1 642<\/td>\n

2594<\/p>\n

\u00b1 590<\/td>\n

2483 \u00b1<\/p>\n

651<\/td>\n

2546 \u00b1<\/p>\n

590<\/td>\n

2569 \u00b1<\/p>\n

618<\/td>\n

2650 \u00b1<\/p>\n

608<\/td>\n

2428 \u00b1<\/p>\n

551<\/td>\n<\/tr>\n

Proteins (%)<\/strong><\/td>\n12,94 \u00b1<\/p>\n

3,91<\/td>\n

13,15 \u00b1<\/p>\n

3,87<\/td>\n

12,68 \u00b1<\/p>\n

3,80<\/td>\n

13,77 \u00b1<\/p>\n

4,04<\/td>\n

12,78 \u00b1<\/p>\n

3,64cc<\/td>\n

13,08 \u00b1<\/p>\n

4,00<\/td>\n

12,47 \u00b1<\/p>\n

3,20<\/td>\n

13,71 \u00b1<\/p>\n

4,70<\/td>\n<\/tr>\n

Lipids (%)<\/strong><\/td>\n34,62 \u00b1<\/p>\n

10,64<\/td>\n

34,25 \u00b1<\/p>\n

9,85<\/td>\n

34,54 \u00b1<\/p>\n

11,01<\/td>\n

34,54 \u00b1<\/p>\n

8,95<\/td>\n

35,85 \u00b1<\/p>\n

10,20<\/td>\n

33,98 \u00b1<\/p>\n

10,53<\/td>\n

33,82 \u00b1<\/p>\n

10,70<\/td>\n

36,25 \u00b1<\/p>\n

10,24<\/td>\n<\/tr>\n

Carbohydrates (%)<\/strong><\/td>\n52,61 \u00b1<\/p>\n

10,74<\/td>\n

52,40 \u00b1<\/p>\n

11,42<\/td>\n

52,94 \u00b1<\/p>\n

11,03<\/td>\n

51,62 \u00b1<\/p>\n

10,48<\/td>\n

51,59 \u00b1<\/p>\n

10,02<\/td>\n

52,97 \u00b1<\/p>\n

11,21<\/td>\n

53,96 \u00b1<\/p>\n

10,40<\/td>\n

50,04 \u00b1<\/p>\n

10,74<\/td>\n<\/tr>\n

Simple sugars (g)<\/strong><\/td>\n12,67 \u00b1<\/p>\n

5,70<\/td>\n

10,31 \u00b1<\/p>\n

3,83<\/td>\n

12,96 \u00b1<\/p>\n

5,82**<\/p>\n

 <\/td>\n

10,13 \u00b1<\/p>\n

3,59<\/td>\n

10,65 \u00b1<\/p>\n

4,20<\/td>\n

12,79 \u00b1<\/p>\n

5,76<\/td>\n

13,12 \u00b1<\/p>\n

6,24<\/td>\n

12,10 \u00b1<\/p>\n

4,51<\/td>\n<\/tr>\n

SFA (%)<\/strong><\/td>\n6,84 \u00b1<\/p>\n

2,49<\/td>\n

8,14 \u00b1<\/p>\n

2,94<\/td>\n

6,63 \u00b1<\/p>\n

2,39<\/td>\n

8,37 \u00b1<\/p>\n

2,84<\/td>\n

5,89 \u00b1<\/p>\n

1,71c<\/td>\n

7,65 \u00b1<\/p>\n

2,79<\/td>\n

6,57 \u00b1<\/p>\n

2,52<\/td>\n

7,44 \u00b1<\/p>\n

2,50<\/td>\n<\/tr>\n

MUFA (%)<\/strong><\/td>\n21,07 \u00b1<\/p>\n

8,03<\/td>\n

20,04 \u00b1<\/p>\n

6,80<\/td>\n

21,13 \u00b1<\/p>\n

8,31<\/td>\n

20,13 \u00b1<\/p>\n

6,23<\/td>\n

21,72 \u00b1<\/p>\n

8,44<\/td>\n

20,47 \u00b1<\/p>\n

7,48<\/td>\n

20,38 \u00b1<\/p>\n

7,55<\/td>\n

22,37 \u00b1<\/p>\n

8,50<\/td>\n<\/tr>\n

PUFA (%)<\/strong><\/td>\n4,42 \u00b1<\/p>\n

2,10<\/td>\n

4,39 \u00b1<\/p>\n

3,14<\/td>\n

4,45 \u00b1<\/p>\n

2,18<\/td>\n

4,31 \u00b1<\/p>\n

2,75<\/td>\n

4,67 \u00b1<\/p>\n

2,94<\/td>\n

4,30 \u00b1<\/p>\n

2,06<\/td>\n

4,53 \u00b1<\/p>\n

2,40d<\/td>\n

4,20 \u00b1<\/p>\n

1,41<\/td>\n<\/tr>\n

Fiber (g)<\/strong><\/td>\n33,03 \u00b1<\/p>\n

17,51<\/td>\n

29,01 \u00b1<\/p>\n

12,89<\/td>\n

34,04 \u00b1<\/p>\n

17,67<\/td>\n

27,40 \u00b1<\/p>\n

12,77<\/td>\n

30,13 \u00b1<\/p>\n

12,03<\/td>\n

32,99 \u00b1<\/p>\n

18,24<\/td>\n

34,62 \u00b1<\/p>\n

19,47<\/td>\n

30,38<\/p>\n

12,90<\/td>\n<\/tr>\n

Cholesterol (mg)<\/strong><\/td>\n293,33 \u00b1<\/p>\n

244,04<\/td>\n

325,19 \u00b1<\/p>\n

327,30<\/td>\n

279,0 \u00b1<\/p>\n

240,46<\/td>\n

353,5 \u00b1<\/p>\n

310,90<\/td>\n

271,0 \u00b1<\/p>\n

200,37<\/td>\n

312,70 \u00b1<\/p>\n

285,73<\/td>\n

291,02 \u00b1<\/p>\n

265,58<\/td>\n

291,00 \u00b1<\/p>\n

200,70<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids.<\/p>\n

**: significantly different (p<0.01) by comparison of PR+ to PR-.<\/p>\n

The cholesterol intake was too high in 40% of patients (table 3). These intakes were significantly greater in premenopausal women than in postmenopausal women (p < 0.01).<\/p>\n

The fiber content of food was low in approximately 31% of patients. Obese women consumed\u00a0significantly lower amounts of fiber than non-obese women (p < 0.05).<\/p>\n

The majority of the patients (92%) had very low Ca intakes. On the other hand, phosphorus intakes were very high compared to the recommendations in 93% of cases.<\/p>\n

Mg, Zn and Se intakes were insufficient in 43%, 35% and 48% of cases respectively, but Fe intake was satisfactory in 74% of patients.<\/p>\n

For fat-soluble vitamins, approximately 66%, 45% and 91% of patients had very low intakes of vitamins A, E and D respectively. As for water-soluble vitamins, it should be noted that the intakes were insufficient in vitamin C for 32%, B1 for 24%, B2 for 35.2%, B6 for 10%, B9\u00a0for 62.6%, and B12 for 54%. The comparison of the BC subtypes did not show any significant difference for energy and macronutrient intake (table 4). However, significantly lower Vit A values (p < 0.05) were noted for ER+, PR+, HER2+ and luminal A compared to ER-, PR-,\u00a0HER- and luminal B respectively (Table 5). The same was true for Vit B2 whose intake was significantly lower for ER+ and PR+ compared to ER- and PR- subtypes respectively (p < 0.001) and for Vit B12 with a lower value (p < 0.001) for the HER2+ compared to HER2-\u00a0subtype (table 5).<\/p>\n

Table 5: Minerals and vitamins intake according to breast cancer subtypes.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\nEstrogen receptor<\/strong><\/td>\nProgesterone receptor<\/strong><\/td>\nHER<\/strong><\/td>\nPhenotype<\/strong><\/td>\n<\/tr>\n
ER+<\/p>\n

(n = 71)<\/td>\n

ER-<\/p>\n

(n = 20)<\/td>\n

PR+<\/p>\n

(n = 65)<\/td>\n

PR-<\/p>\n

(n = 26)<\/td>\n

HER+<\/p>\n

(n = 27)<\/td>\n

HER-<\/p>\n

(n = 64)<\/td>\n

Luminal A (n = 45)<\/td>\nLuminal B (n = 28)<\/td>\n<\/tr>\n
Vit A (mcg)<\/strong><\/td>\n247,85 \u00b1<\/p>\n

156,05<\/p>\n

***<\/td>\n

373,51 \u00b1<\/p>\n

402,51<\/td>\n

231,64 \u00b1<\/p>\n

120,12<\/p>\n

***<\/td>\n

385,04 \u00b1<\/p>\n

383,09<\/td>\n

222,53 \u00b1<\/p>\n

100,63<\/p>\n

**<\/td>\n

297,80 \u00b1<\/p>\n

271,93<\/td>\n

228,09 \u00b1<\/p>\n

104,63<\/p>\n

**<\/td>\n

314,22 \u00b1<\/p>\n

283,73<\/td>\n<\/tr>\n

Vit D (mcg)<\/strong><\/td>\n9,66 \u00b1<\/p>\n

5,24<\/td>\n

9,50 \u00b1<\/p>\n

5,29<\/td>\n

9,72 \u00b1<\/p>\n

5,47<\/td>\n

9,38 \u00b1<\/p>\n

4,63<\/td>\n

7,98 \u00b1<\/p>\n

1,89<\/p>\n

**<\/td>\n

10,32 \u00b1<\/p>\n

5,98<\/td>\n

9,34 \u00b1<\/p>\n

4,16<\/td>\n

10,05 \u00b1<\/p>\n

6,54<\/td>\n<\/tr>\n

Vit E (mg)<\/strong><\/td>\n14,68 \u00b1<\/p>\n

8,66<\/td>\n

11,81 \u00b1<\/p>\n

3,91<\/td>\n

15,11 \u00b1<\/p>\n

8,85<\/td>\n

11,40 \u00b1<\/p>\n

4,05<\/td>\n

15,16 \u00b1<\/p>\n

9,22<\/td>\n

13,58 \u00b1<\/p>\n

7,36<\/td>\n

15,41 \u00b1<\/p>\n

10,03<\/td>\n

13,29 \u00b1<\/p>\n

5,35<\/td>\n<\/tr>\n

Vit C (mg)<\/strong><\/td>\n120,72 \u00b1<\/p>\n

104,62<\/td>\n

95,32 \u00b1<\/p>\n

56,68<\/td>\n

123,48 \u00b1<\/p>\n

104,06<\/td>\n

94,27 \u00b1<\/p>\n

71,68<\/td>\n

110,48 \u00b1<\/p>\n

78,29<\/td>\n

117,10 \u00b1<\/p>\n

103,67<\/td>\n

123,32 \u00b1<\/p>\n

116,46<\/td>\n

116,29 \u00b1<\/p>\n

79,29<\/td>\n<\/tr>\n

Vit B1 (mg)<\/strong><\/td>\n1,18 \u00b1<\/p>\n

0,46<\/td>\n

1,11 \u00b1<\/p>\n

0,45<\/td>\n

1,19 \u00b1<\/p>\n

0,46<\/td>\n

1,10 \u00b1<\/p>\n

0,45<\/td>\n

1,11 \u00b1<\/p>\n

0,39<\/td>\n

1,19 \u00b1<\/p>\n

0,48<\/td>\n

1,23 \u00b1<\/p>\n

0,52<\/td>\n

1,09 \u00b1<\/p>\n

0,31<\/td>\n<\/tr>\n

Vit B2 (mg)<\/strong><\/td>\n1,17 \u00b1<\/p>\n

0,50<\/p>\n

***<\/td>\n

1,63 \u00b1<\/p>\n

2,21<\/td>\n

1,16 \u00b1<\/p>\n

0,50<\/p>\n

***<\/td>\n

1,55 \u00b1<\/p>\n

1,95<\/p>\n

 <\/td>\n

1,03 \u00b1<\/p>\n

0,37<\/td>\n

1,37 \u00b1<\/p>\n

1,31<\/td>\n

1,17 \u00b1<\/p>\n

0,49<\/td>\n

1,17 \u00b1<\/p>\n

0,52<\/td>\n<\/tr>\n

VIT B6 (mg)<\/strong><\/td>\n1,98 \u00b1<\/p>\n

0,87<\/td>\n

1,89 \u00b1<\/p>\n

0,73<\/td>\n

2,00 \u00b1<\/p>\n

0,86<\/td>\n

1,85 \u00b1<\/p>\n

0,78<\/td>\n

1,78 \u00b1<\/p>\n

0,65<\/td>\n

2,04 \u00b1<\/p>\n

0,90<\/td>\n

1,97 \u00b1<\/p>\n

0,78<\/td>\n

1,99 \u00b1<\/p>\n

0,98<\/td>\n<\/tr>\n

Vit B9 (mg)<\/strong><\/td>\n317,02 \u00b1<\/p>\n

122,94<\/td>\n

289,59 \u00b1<\/p>\n

168,55<\/td>\n

319,57 \u00b1<\/p>\n

119,20<\/td>\n

289,54 \u00b1<\/p>\n

165,35<\/td>\n

297,90 \u00b1<\/p>\n

115,15<\/td>\n

316,51 \u00b1<\/p>\n

141,32<\/td>\n

321,65 \u00b1<\/p>\n

118,76<\/td>\n

305,83 v<\/p>\n

127,55<\/td>\n<\/tr>\n

Vit B12 (mg)<\/strong><\/td>\n3,05 \u00b1<\/p>\n

2,48<\/td>\n

3,27 \u00b1<\/p>\n

2,19<\/td>\n

3,09 \u00b1<\/p>\n

2,59<\/td>\n

3,12 \u00b1<\/p>\n

1,95<\/td>\n

2,27\u00b1<\/p>\n

0,97<\/strong><\/p>\n

***<\/strong><\/td>\n

3,45 \u00b1<\/p>\n

2,74<\/td>\n

2,82 \u00b1<\/p>\n

1,97<\/td>\n

3,44 \u00b1<\/p>\n

3,08<\/td>\n<\/tr>\n

Mg (mg)<\/strong><\/td>\n311,93 \u00b1<\/p>\n

124,12<\/td>\n

275,37 \u00b1<\/p>\n

104,74<\/td>\n

317,93 \u00b1<\/p>\n

124,57<\/td>\n

268,82 \u00b1<\/p>\n

103,87<\/td>\n

297,46 \u00b1<\/p>\n

115,90<\/td>\n

306,61 \u00b1<\/p>\n

123,24<\/td>\n

326,57 \u00b1<\/p>\n

139,93d<\/td>\n

284,68 \u00b1<\/p>\n

84,51<\/td>\n<\/tr>\n

Ca (mg)<\/strong><\/td>\n553,66 \u00b1<\/p>\n

260,52<\/td>\n

541,19 \u00b1<\/p>\n

224,66<\/td>\n

563,04 \u00b1<\/p>\n

267,71<\/td>\n

520,63 \u00b1<\/p>\n

209,00<\/td>\n

499,62 \u00b1<\/p>\n

176,33<\/td>\n

572,56 \u00b1<\/p>\n

276,10<\/td>\n

569,13 \u00b1<\/p>\n

288,96<\/td>\n

533,34 \u00b1<\/p>\n

199,58<\/td>\n<\/tr>\n

P (mg)<\/strong><\/td>\n1317,33 \u00b1<\/p>\n

481,87<\/td>\n

1248,27 \u00b1<\/p>\n

467,74<\/td>\n

1322,04 \u00b1<\/p>\n

494,68<\/td>\n

1252,45<\/p>\n

\u00b1<\/p>\n

435,14<\/td>\n

1216,07<\/p>\n

\u00b1<\/p>\n

378,68<\/td>\n

1338,47<\/p>\n

\u00b1<\/p>\n

511,34<\/td>\n

1336,09<\/p>\n

\u00b1<\/p>\n

507,86<\/td>\n

1283,29<\/p>\n

\u00b1<\/p>\n

425,12<\/td>\n<\/tr>\n

\u00a0Fe (mg)<\/strong><\/td>\n13,99 \u00b1<\/p>\n

9,53<\/td>\n

12,93 \u00b1<\/p>\n

9,53<\/td>\n

14,15 \u00b1<\/p>\n

9,88<\/td>\n

12,75 \u00b1<\/p>\n

8,53<\/td>\n

12,13 \u00b1<\/p>\n

4,86<\/td>\n

14,44 \u00b1<\/p>\n

10,83<\/td>\n

14,68 \u00b1<\/p>\n

11,49<\/td>\n

12,64 \u00b1<\/p>\n

4,33<\/td>\n<\/tr>\n

Zn (mg)<\/strong><\/td>\n8,06 \u00b1<\/p>\n

2,92<\/td>\n

8,54 \u00b1<\/p>\n

4,91<\/td>\n

8,08 \u00b1<\/p>\n

2,79<\/td>\n

8,38 \u00b1<\/p>\n

4,73<\/td>\n

7,51 \u00b1<\/p>\n

2,41c<\/td>\n

8,44 \u00b1<\/p>\n

3,76<\/td>\n

8,24 \u00b1<\/p>\n

2,87<\/td>\n

7,89 \u00b1<\/p>\n

2,98<\/td>\n<\/tr>\n

Se (mcg)<\/strong><\/td>\n48,89 \u00b1<\/p>\n

22,08<\/td>\n

48,42 \u00b1<\/p>\n

24,94<\/td>\n

48,82 \u00b1<\/p>\n

22,13<\/td>\n

48,70 \u00b1<\/p>\n

24,17<\/td>\n

43,52 \u00b1<\/p>\n

20,02<\/td>\n

51,01 \u00b1<\/p>\n

23,39<\/td>\n

49,07 \u00b1<\/p>\n

22,66<\/td>\n

48,74 \u00b1<\/p>\n

20,70<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

**: significantly different at p<0.01, ***: significantly different at p<0.001 by comparison of ER + to ER-, PR+ to PR-, HER+ to HER-, and luminal A to luminal B.<\/p>\n

Discussion<\/strong><\/p>\n

This work represents the first study of the main anthropometric and nutritional characteristics of Moroccan women with BC. According to our results, about 38% of the patients were obese. This value is higher than the value of 29 % reported on Moroccan women18<\/sup>. An\u00a0increase in body weight in women with BC was previously reported19<\/sup>. Based on BMI, % Fat and waist-to-hip ratio, the participants in our study mainly suffered from abdominal obesity. The results also showed that overweight and obesity, particularly abdominal obesity, affect\u00a0 postmenopausal women more than premenopausal womenSome studies noted weight gain in neo-adjuvant therapy in 50 – 96% of women with BC20,21<\/sup>. This excess weight can be a factor of poor prognosis for patients. In fact, obese women are more likely to have large tumors,\u00a0advanced disease at diagnosis, high rates of metastasis and can develop resistance to endocrine therapy22,23<\/sup>. Obesity was also associated with a significant increase in the risk of death from all causes and a marginally significant risk of mortality from BC19<\/sup>. In this regard,\u00a0Flanagan et al.24<\/sup> \u00a0reported that an increase of 1 kg \/ m2<\/sup> in BMI would imply a 3% increase in the probability of recurrence of BC; and that women who were obese at the time of BC diagnosis had a 1.6 times higher risk of recurrence than women with a normal BMI. Other\u00a0authors noted the existence of an increased risk of developing second BC and a poor prognosis associated with obesity and \/ or weight gain25,26<\/sup>. Obesity and overweight can also affect the effectiveness of antineoplastic treatments, increase their side effects and complicate\u00a0management due to related comorbidities such as hypertension, hyperlipemia and diabetes27<\/sup>. Indeed, the fat mass in particular the visceral fat responsible for abdominal obesity is a metabolically active fat21<\/sup>. It secretes several substances such as adipokines, growth factors\u00a0and inflammatory cytokines. These molecules are involved in cell survival or apoptosis, angiogenesis, migration and proliferation21<\/sup>, which allows them to play an important role in the occurrence, development, recurrence, metastasis and mortality from BC28,29<\/sup>.<\/p>\n

In general, the nutritional contributions recorded by our study were very unbalanced. Energy intakes were very high in the majority of patients, especially those in post-menopause. Their carbohydrate intakes, especially simple sugars, were very high. These factors, combined with\u00a0a sedentary lifestyle, explain the overweight and obesity recorded, especially among postmenopausal women. Excessive intakes can promote tumor growth30<\/sup>. Likewise, high intakes of saturated fat increase the risk of mortality due to BC, but also due to associated comorbidities31<\/sup>.<\/p>\n

Food intake of vitamin A, D and E was low in the majority of our patients. This finding hardly comforts the patients. Indeed, large intakes of \u03b2-carotene (provitamin A) in pre-diagnosis of BC were significantly associated with an improvement in overall survival32<\/sup>. We\u00a0also observed significantly lower intakes of Vit A in women with positive markers of ER, PR and HER subtypes. These results are in agreement with those of Cui et al.33 <\/sup>who report an inverse association between the risk of BC and dietary carotenoids in menopausal women\u00a0with ER + and PR +. Similarly, the vitamin D deficiency observed in our study is thought to be one of the risk and mortality factors associated with BC34<\/sup>. Vitamin D is involved in the differentiation, proliferation and apoptosis of epithelial cells. A normal serum 25 Hydroxy \u2013Vit D level (> 30ng \/ mL) at diagnosis was significantly correlated with an improvement in\u00a0BC-specific survival at least after 3 years of follow-up35-37<\/sup>. Vitamin E also has pro-apoptotic, antiproliferative and angiogenesis inhibitory activities38,39<\/sup>. It could also be associated with antineoplastic therapies to fight against metastases and improve immune and anti-inflammatory functions38-40<\/sup>. In fact, adequate vitamin E intake was associated with a\u00a0 decreased risk of recurrence of BC and overall mortality38,41,42<\/sup>.<\/p>\n

Vitamin B9 and B12 intakes were low in 62% and 52% of the women interviewed, respectively. This deficiency can have negative consequences on women with BC, as folates play an important role in DNA synthesis, methylation and repair43-45<\/sup>. However,\u00a0 supplementation of the diet with folates must take into account that in high doses this vitamin constitutes a risk factor for the development of cancers46<\/sup>. Vitamin B12 can have a positive effect in BC. Its use before and during chemotherapy allowed a significant increase in BC\u00a0survival47-50<\/sup>. In addition, various forms of Vit B12 showed anti-tumor activity. Thus, methylcobalamin slowed tumor growth and induced apoptosis in carcinoma cells in mice, although growth promoters such as androgens have been used51,52<\/sup>. The 5′-\u00a0deoxyadenosylcobalamin and methylcobalamin have cytotoxic properties53<\/sup>.<\/p>\n

Methylcobalamin, in addition to its action on tumor growth, increased survival time in mice54<\/sup>.<\/p>\n

Another factor compromising the patients\u2019 prognosis is the low intake of vitamin C. Indeed, several studies supported the fact that an adequate intake of vitamin C was associated with a\u00a0reduction in the risk of recurrence and \/ or mortality in patients with BC55,56<\/sup>. High doses of vitamin C induce apoptosis, reduce cell proliferation and the number of invading cancer cells, and prevent metastasis57<\/sup>. These effects are even more marked in cases of aggressive BC, as is the case with that of the triple negative subtype58<\/sup>.<\/p>\n

Our results also showed that the Ca, Mg, Zn and Se intakes were below the required values. Even if the relationship between Ca and BC intakes is not yet well established, this mineral may be involved in breast carcinogenesis through its important role in the regulation of cell\u00a0proliferation, differentiation and apoptosis59,60<\/sup>. In fact, a high calcium intake decreases breast carcinogenesis and the uncontrolled proliferation of epithelial cells induced by fat in the breast and \/ or by a chemical carcinogen in rodents61,62<\/sup>. On another hand, low intakes of\u00a0magnesium could compromise patient survival. Indeed, a deficiency in Mg can alter certain biological functions in women with BC, in particular those linked to cell proliferation and signaling, and DNA synthesis and repair63,64<\/sup>. However, any additional intake of Mg must take\u00a0into account that of Ca, since the latter behaves as a competitor for Mg, particularly in terms of intestinal absorption65<\/sup>. Deficiencies in Zn and Se, associated with those of vitamins C and E, can lead to an increase in cellular oxidative stress, which would lead to DNA damage33<\/sup>. In fact, the development of BC is accompanied by oxidative stress, which increases with the progression of the disease and the levels of antioxidant defenses decrease during\u00a0antineoplastic treatments66,67<\/sup>. In addition to their antioxidant role, vitamin E, vitamin C and Se selectively induce apoptosis in cancer cells66,68,69<\/sup>. Furthermore, Zn and organic Se inhibit tumor growth and provide more protection against BC metastasis70,71<\/sup>.<\/p>\n

Conclusion<\/strong><\/p>\n

The nutritional profile of Moroccan women with BC showed many imbalances. On the one hand, the intakes of energy, free sugars and saturated fatty acids were high. On the other hand, vitamins A, D, E, B9, B12 and the trace element Zn and Se showed a significant deficit. Improving nutritional quality would help fight against the occurrence of breast cancer and help patients recover better following antineoplastic treatments.<\/p>\n

Acknowledgement\u00a0<\/strong><\/p>\n

We would like to thank all the respondents who participated in this work.<\/p>\n

Conflict Interest<\/strong><\/p>\n

None<\/p>\n

Funding Source <\/strong><\/p>\n

None<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Sung H, Ferlay J, Siegel R. L, Laversanne M, Soerjomataram I, Jemal A and Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin., 2021; 71: 209\u2013249.
    \nCrossRef<\/a><\/li>\n
  2. Potter J. D, Cerhan J. R, Sellers T. A, McGovern P. G, Drinkard C, Kushi L. R and Folsom A., R. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women\u2019s Health Study: how many kinds of breast cancer are there? Cancer Epidemiol. Biomarkers Prev., 1995; 4: 319-326.
    \nCrossRef<\/li>\n
  3. Althuis M. D, Fergenbaum J. H, Garcia-Closas M, Brinton L, Madigan M. P and Shermanet M. E. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol. Biomarkers Prev., 2004; 13: 1558-1568.
    \n    CrossRef<\/a><\/li>\n
  4. Li C. I, Malone K. E, Porter P. L, Weiss N. S, Tang M. T, Cushing-Haugen K. L and Daling J. R. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA., 2003; 289: 3254-3263.
    \n    CrossRef<\/a><\/li>\n
  5. Suzuki R, Orsini N, Saji S. Key T. J and Wolk A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status: a meta-analysis. Int. J. Cancer, 2009; 124: 698-712.
    \n    CrossRef<\/a><\/li>\n
  6. Momenimovahed Z and Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer – Targets and Therapy, 2019; 11: 151\u2013164.
    \n    CrossRef<\/a><\/li>\n
  7. Franceschi S, Parpinel M, La Vecchia C et al. Role of different types of vegetables and fruit in the prevention of cancer of the colon, rectum, and breast. Epidemiology, 1998; 9: 338341.
    \n    CrossRef<\/a><\/li>\n
  8. Tavani A, Pelucchi C, Parpinel M, Negri E, Franceschi S, Levi F and La Vecchia C. n-3 polyunsaturated fatty acid intake and cancer risk in Italy and Switzerland. Int. J. Cancer, 2003; 105: 113-116.
    \n    CrossRef<\/a><\/li>\n
  9. Patterson R, Neuhouser M, Hedderson M, Schwartz S, Standish L and Bowen D. J. Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J. Am. Diet. Assoc., 2003; 103: 323\u2013328.
    \n    CrossRef<\/a><\/li>\n
  10. Thomson C. A, Flatt S. W, Rock C. L, Ritenbaugh C, Newman V and Pierce J. P. Increased fruit, vegetable and fiber intake and lower fat intake reported among women previously treated for invasive breast cancer. J. Am. Diet Assoc., 2002; 102: 801\u2013808.
    \n    CrossRef<\/a><\/li>\n
  11. Ferreira I. B, Eda C. M, Cust\u00f3dio I. D, Gontijo C. A, Paiva C. E, Crispim C. A, Maia Y. C. Food intake and the nutritional status of women undergoing chemotherapy. Cien Saude Colet, 2016; 21 (7): 2209-2218.
    \n    CrossRef<\/a><\/li>\n
  12. Cust\u00f3dio I. D. D, Marinho E. D. C, Gontijo C. A, Pereira T. S, Paiva C. E and Maia Y. C. Impact of chemotherapy on diet and nutritional status of women with breast cancer: A prospective study; PLoS One, 2016; 11 (6): e0157113 2016.
    \n    CrossRef<\/a><\/li>\n
  13. H\u00e9buterne X, Lemari\u00e9 E, Michallet M, de Montreuil C. B, Schneider S. M and Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. J. Parenter. Enteral. Nutr., 2014; 38 (2:, 196-204.
    \n    CrossRef<\/a><\/li>\n
  14. Bradshaw P. T, Stevens J, Khankari N, Teitelbaum S. L, Neugut A. I and Gammon M. D. Cardiovascular disease mortality among breast cancer survivors. Epidemiol. Camb. Mass., 2016; 27: 6\u201313.
    \n    CrossRef<\/a><\/li>\n
  15. World Health Organization. Global Health Observatory. Geneva: World Health Organization; 2018. who.int\/gho\/database\/en\/. Accessed July 17, 2018.<\/li>\n
  16. World Health Organization. Waist circumference and waist\u2013hip ratio: Report of a WHO expert consultation, Geneva, 8\u201311 December 2008.<\/li>\n
  17. Institute of Medicine of the National Aademies. Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. Washington, DC: The National Academies Press; 2006.<\/li>\n
  18. FAO, IFAD, UNICEF, WFP and WHO. The state of food security and nutrition in the world 2017. Building resilience for peace and food security. Rome, 2017.<\/li>\n
  19. Caan B. J, Kwan M. L, Hartzell G, Castillo A, Slattery M. L, Sternfeld B and Weltzien E. Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer.\u00a0Cancer Causes Control, 2008; 19 (10): 1319-1328.
    \n    CrossRef<\/a><\/li>\n
  20. Demark-Wahnefried W, Rimer B. K and Winer E. P. Weight gain in women diagnosed with breast cancer.\u00a0J. Am. Diet Assoc., 1997; 97 (5): 519\u2010528.
    \n    CrossRef<\/a><\/li>\n
  21. Demark-Wahnefried W, Winer E. P and Rimer B. K. Why women gain weight with adjuvant chemotherapy for breast cancer. J. Clin. Oncol., 1993; 11( 7): 1418\u20101429.
    \n    CrossRef<\/a><\/li>\n
  22. Chan D. S, Vieira A. R, Aune D, Bandera E. V, Greenwood D. C, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R and Norat T. Body mass index and survival in women with breast cancer. Systematic literature review and meta-analysis of 82 follow-up studies. Ann. Oncol., 2014; 25 (10): 1901-1914.
    \n    CrossRef<\/a><\/li>\n
  23. Santa-Maria C. A, Yan J, Xie X. J and Euhus D. M. Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index. Int. J. Clin. Oncol., 2015; 20 (2): 317\u2010323.
    \n    CrossRef<\/a><\/li>\n
  24. Flanagan M. R, Tang M. C, Baglia M. L, Porter P. L, Malone K. E and Li C. I. Relationship between anthropometric factors and risk of second breast cancer among women with a history of ductal carcinoma in situ. JNCI Cancer Spectr., 2018; 2 (2): pky020.
    \n    CrossRef<\/a><\/li>\n
  25. Chan D. S and Norat T. Obesity and breast cancer: not only a risk factor of the disease. Curr. Treat. Options Oncol., 2015; 16 (5): 22.
    \n    CrossRef<\/a><\/li>\n
  26. Kwan M. L, Chen W. Y, Kroenke C. H, Weltzien E. K, Beasley J. M, Nechuta S. J, Poole E. M, Lu W, Holmes M. D, Quesenberry C. P. Jr, Pierce J. P, Shu X. O and Caan B. J. Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Res. Treat., 2012; 132(2): 729-739.
    \n    CrossRef<\/a><\/li>\n
  27. Sheean P. M, Hoskins K and Stolley M. Body composition changes in females treated for breast cancer: a review of the evidence. Breast Cancer Res. Treat., 2012; 135 (3): 663\u2010680.
    \n    CrossRef<\/a><\/li>\n
  28. Fox C. S, Massaro J. M, Hoffmann U, Pou K. M, Maurovich-Horvat P, Liu C. Y, Vasan R. S, Murabito J. M, Meigs J. B, Cupples L. A, D’Agostino R. B. Sr and O’Donnell C. J. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.\u00a0Circulation, 2007; 116 (1): 39\u201048.
    \n    CrossRef<\/a><\/li>\n
  29. Hursting S. D and Berger N. A. Energy balance, host-related factors, and cancer progression. J. Clin. Oncol., 2010; 28 (26): 4058\u20104065.<\/li>\n
  30. MacLennan M and Ma D. W. Role of dietary fatty acids in mammary gland development and breast cancer. Breast Cancer Res., 2010; 12 (5): 211.
    \n    CrossRef<\/a><\/li>\n
  31. Brennan S. F, Woodside J. V, Lunny P. M, Cardwell C. R and Cantwell M. M. Dietary fat and breast cancer mortality: A systematic review and meta-analysis. Crit. Rev. Food. Sci. Nutr.; 2017; 57 (10):1999-2008.
    \n    CrossRef<\/a><\/li>\n
  32. He J, Gu Y and Zhang S. Vitamin A and breast cancer survival: A systematic review and meta-analysis. Clin. Breast Cancer, 2018; 18 (6): e1389-e1400.
    \n    CrossRef<\/a><\/li>\n
  33. Cui Y, Shikany J. M, Liu S; Shagufta Y and Rohan T. E. Selected antioxidants and risk of hormone receptor\u2013defined invasive breast cancers among postmenopausal women in the Women\u2019s Health Initiative Observational Study. Am. J. Clin. Nutr., 2008; 87: 1009\u20131018.
    \n    CrossRef<\/a><\/li>\n
  34. Sheng L, Callen D. F and Turner A. G. Vitamin D3 signaling and breast cancer: Insights from transgenic mouse models. J. Steroid. Biochem. Mol. Biol., 2018; 178: 348-353.
    \n    CrossRef<\/a><\/li>\n
  35. Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T, Brouckaert O, Peuteman G, Laenen A, Verlinden L, Kriebitzsch C, Dieudonn\u00e9 A. S, Paridaens R, Neven P, Christiaens M. R, Bouillon R and Wildiers H.. Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis, 2012; 33 (7): 1319\u20131326.
    \n    CrossRef<\/a><\/li>\n
  36. Vrieling A, Seibold P and Theron S. Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors. Int. J. Cancer, 2014; 15; 134(12): 2972-2983.
    \n    CrossRef<\/a><\/li>\n
  37. Yao S, Kwan M. L and Isaac J. Higher serum levels of vitamin D at diagnosis are associated with better survival in a prospective cohort of 1,666 women with breast cancer: A case-cohort analysis in the Pathways Study. JAMA Oncol., 2017; 3 (3): 351\u2013357.
    \n    CrossRef<\/a><\/li>\n
  38. Rizvi S, Raza S. T, Ahmed F, Ahmad A, Abbas S and Mahdi F. The role of vitamin E in human health and some diseases. Sultan Qaboos Univ. Med. J., 2014; 14 (2): e157-e165.<\/li>\n
  39. Alawin O. A; Ahmed R. A, Ibrahim B. A, Briski K. P and Sylvester P. W. Antiproliferative effects of \u03b3-tocotrienol are associated with lipid raft disruption in HER2-positive human breast cancer cells. J. Nutr. Biochem., 2016; 27, 266\u2013277.
    \n    CrossRef<\/a><\/li>\n
  40. Aggarwal V, Kashyap D, Sak K, Tuli H. S, Jain A, Chaudhary A, Garg V. K, Sethi G and Yerer M. B. Molecular mechanisms of action of tocotrienols in cancer: Recent trends and advancements. Int. J. Mol. Sci., 2019; 20 (3): 656.
    \n    CrossRef<\/a><\/li>\n
  41. Abraham A, Kattoor A. J, Saldeen T and Mehta J. L. Vitamin E and its anticancer effects. Crit. Rev. Food Sci. Nutr., 2019; 59 (17): 2831-2838.
    \n    CrossRef<\/a><\/li>\n
  42. Lee G. Y and Han S. N. The role of vitamin E in immunity. Nutrients; 2018; 10 (11): 1614.
    \n    CrossRef<\/a><\/li>\n
  43. Choi S. W and Mason J. B. Folate and carcinogenesis: an integrated scheme. J. Nutr., 2000; 130:129-132.
    \n    CrossRef<\/a><\/li>\n
  44. Duthie S. J, Narayanan S, Brand G. M, Pirie L and Grant G. Impact of folate deficiency on DNA stability. J. Nutr., 2002; 132: 2444\u20132449.
    \n    CrossRef<\/a><\/li>\n
  45. Lewis S. J, Harbord R. M, Harris R and Smith G. D. Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. J. Natl. Cancer Inst., 2006; 98: 1607-1622.
    \n    CrossRef<\/a><\/li>\n
  46. Kim Y. Folate: a magic bullet or a double-edged sword for colorectal cancer prevention? Gut., 2006; 55: 1387\u20131389.
    \n    CrossRef<\/a><\/li>\n
  47. Lajous M, Romieu I, Sabia S, Boutron-Ruault M. C and Clavel-Chapelon F. Folate, vitamin B12 and postmenopausal breast cancer in a prospective study of French women.\u00a0Cancer Causes Control.;, 2006; 17 (9): 1209-1213.
    \n    CrossRef<\/a><\/li>\n
  48. Willett C. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer., J. Natl. Cancer Inst.,\u00a02003; 95(5): 373-380.
    \n    CrossRef<\/a><\/li>\n
  49. Wu W, Kang S and Zhang D. Association of vitamin B6, vitamin B12 and methionine with risk of breast cancer: a dose-response meta-analysis. Br. J. Cancer., 2013; 109 (7):1926-1944.
    \n    CrossRef<\/a><\/li>\n
  50. Zhang S. M, Willett W. C, Selhub J, Hunter D. J, Giovannucci E. L, Holmes M. D, Colditz G. A and Hankinson S. E. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J. Natl. Cancer Inst., 2003; 95 (5): 373-380.
    \n    CrossRef<\/a><\/li>\n
  51. Nishizawa Y, Yamamoto T, Terada N, Fushiki S, Matsumoto K and Nishizawa Y. Effects of methylcobalamin on the proliferation of androgensensitive or estrogen-sensitive malignant cells in culture and in vivo. Int. J. Vitam. Nutr. Res., 1997; 67: 164-170.<\/li>\n
  52. Nishizawa Y, Goto H. G, Tanigaki Y and Fushiki S. Induction of apoptosis in an androgen-dependent mouse mammary carcinoma cell line by methylcobalamin. Anticancer Res., 2001; 21: 1107-1110.<\/li>\n
  53. Tsao C. S, Miyashita K and Young M. Cytotoxic activity of cobalamin in cultured malignant and nonmalignant cells. Pathobiology, 1990; 58 (5): 292-296.
    \n    CrossRef<\/a><\/li>\n
  54. Shimizu N, Hamazoe R, Kanayama H, Maeta M and Koga S. Experimental study of antitumor effect of methyl-B12. Oncology, 1987; 44 (3): 169-173.
    \n    CrossRef<\/a><\/li>\n
  55. Harris H. R, Orsini N and Wolk A. Vitamin C and survival among women with breast cancer: a meta-analysis. Eur. J. Cancer., 2014; 50: 1223 \u201312 31.
    \n    CrossRef<\/a><\/li>\n
  56. Hutchinson J, Lentjes M. A. H, Greenwood D. C, Burley V. J, Cade J. E, Cleghorn C. L, Threapleton D. E, Key T. J, Cairns B. J, Keogh R. H, Dahm C. C, Brunner E. J, Shipley M. J, Kuh D, Mishra G, Stephen A. M, Bhaniani A, Borgulya G and Khaw K. T. Vitamin C intake from diary recordings and risk of breast cancer in the UK Dietary Cohort Consortium. Eur. J. Clin. Nutr., 2012; 66: 561\u2013568.
    \n    CrossRef<\/a><\/li>\n
  57. Zeng L. H, Wang Q. M, Feng L. Y, Ke Y. D, Xu Q. Z, Wei A. Y, Zhang C and Ying R. B. High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition. Onco. Targets Ther., 2019; 12: 7405-7413.
    \n    CrossRef<\/a><\/li>\n
  58. Gan L, Camarena V, Mustafi S and Wang G. Vitamin C inhibits triple-negative breast cancer metastasis by affecting the expression of YAP1 and synaptopodin 2. Nutrients, <\/em>2019; 11<\/em>: 2997.
    \n    CrossRef<\/a><\/li>\n
  59. Mathiasen I. S, Sergeev I. N, Bastholm L, Elling F, Norman A. W and J\u00e4\u00e4ttel\u00e4 M. Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. J. Biol. Chem., 2002; 277: 30738 \u201330745.
    \n    CrossRef<\/a><\/li>\n
  60. Sergeev I. N. Calcium as a mediator of 1,25-dihydroxyvitamin D3-induced apoptosis. J. Steroid. Biochem. Mol. Biol., 200 (89-90): 419\u2013425.
    \n    CrossRef<\/a><\/li>\n
  61. Jacobson E. A, James K. A, Newmark H. L and Carroll K. K. Effects of dietary fat, calcium, and vitamin D on growth and mammary tumorigenesis induced by 7,12-dimethylbenz (a) anthracene in female Sprague-Dawley rats. Cancer Res., 1989; 49: 6300\u20136303.<\/li>\n
  62. Xue L, Lipkin M, Newmark H and Wang J. Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice. J. Natl. Cancer Inst., 1999; 91: 176\u2013181.
    \n    CrossRef<\/a><\/li>\n
  63. Blaszczyk U and Duda-Chodak A. Magnesium: its role in nutrition and carcinogenesis. Rocz. Panstw. Zakl. Hig., 2013; 64 (3): 165\u2013171.
    \nCrossRef<\/li>\n
  64. Yang L, Arora K, Beard W. A, Wilson S. H and Schlick T. Critical role of magnesium ions in DNA polymerase beta\u2019s closing and active site assembly. J. Am. Chem. Soc., 126 (27): 8441\u20138453.
    \n    CrossRef<\/a><\/li>\n
  65. Hardwick L. L, Jones M. R, Brautbar N and Lee D. B. Magnesium absorption: mechanisms and the influence of vitamin D, calcium and phosphate. J. Nutr., 1991; 121: 13-23.
    \n    CrossRef<\/a><\/li>\n
  66. Borek C. Dietary antioxidants and human cancer. Integr. Cancer Ther., 2004; 3(4): 333-341.
    \n    CrossRef<\/a><\/li>\n
  67. Khanzode S. S, Muddeshwar M. G, Khanzode S. D and Dakhale G. N. Antioxidant enzymes and lipid peroxidation in different stages of breast cancer. Free Radic. Res., 2004; 38: 81-85.
    \n    CrossRef<\/a><\/li>\n
  68. Borek C and Pardo F. Vitamin E and apoptosis: a dual role. In: Pasquier C, ed. Biennial Meeting of the Society for Free Radicals Research International. Paris, France, July 16-20, 2002. Monduzzi Editore, Bologna, Italy, 1994:327-331.<\/li>\n
  69. Sigounas G, Anagnostu A and Steiner M. Dl-alpha tocopherol induces apoptosis in erythroleukemia, prostate and breast cancer cells. Nutr. Cancer, 1997; 28: 30-35.
    \n    CrossRef<\/a><\/li>\n
  70. Chen Y. C, Prabhu K. S, Das A and Mastro A. M. Dietary selenium supplementation modifies breast tumor growth and metastasis. Int. J. Cancer, 2013; 133 (9): 2054-2064.
    \n    CrossRef<\/a><\/li>\n
  71. Wu X, Tang J and Xie M. Serum and hair zinc levels in breast cancer: a meta-analysis. Sci. Rep., 2015; 5: 12249.
    \n    CrossRef<\/a><\/li>\n<\/ol>\n

    Abbreviations<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
    BC<\/strong><\/td>\n:<\/td>\nBreast Cancer<\/td>\n<\/tr>\n
    BF<\/strong><\/td>\n:<\/td>\nBody Fat<\/td>\n<\/tr>\n
    ER<\/strong><\/td>\n:<\/td>\nEstrogen Receptor<\/td>\n<\/tr>\n
    FM<\/strong><\/td>\n:<\/td>\nFat Mass<\/td>\n<\/tr>\n
    HER<\/strong><\/td>\n:<\/td>\nHuman Epidermal Growth Factor Receptor<\/td>\n<\/tr>\n
    LM<\/strong><\/td>\n:<\/td>\nLean Mass<\/td>\n<\/tr>\n
    MBI<\/strong><\/td>\n:<\/td>\nMass Body Index<\/td>\n<\/tr>\n
    PR<\/strong><\/td>\n:<\/td>\nProgesterone Receptor<\/td>\n<\/tr>\n
    VF<\/strong><\/td>\n:<\/td>\nVisceral Fat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

    Introduction Among tumors, breast cancer (BC) is one of the […]<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[94],"tags":[],"class_list":["post-41537","post","type-post","status-publish","format-standard","hentry","category-vol14no4"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/41537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=41537"}],"version-history":[{"count":6,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/41537\/revisions"}],"predecessor-version":[{"id":42642,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/41537\/revisions\/42642"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=41537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=41537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=41537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}